[Federal Register Volume 63, Number 181 (Friday, September 18, 1998)]
[Notices]
[Pages 49916-49917]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-25033]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention
[INFO-98-29]


Proposed Data Collections Submitted for Public Comment and 
Recommendations

    In compliance with the requirement of Section 3506(c)(2)(A) of the 
Paperwork Reduction Act of 1995 for opportunity for public comment on 
proposed data collection projects, the Centers for Disease Control and 
Prevention (CDC) will publish periodic summaries of proposed projects. 
To request more information on the proposed projects or to obtain a 
copy of the data collection plans and instruments, call the Assistant 
CDC Reports Clearance Officer on (404) 639-7090.
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques for other 
forms of information technology. Send comments to Seleda M. Perryman, 
Assistant CDC Reports Clearance Officer, 1600 Clifton Road, MS-D24, 
Atlanta, GA 30333. Written comments should be received within 60 days 
of this notice.

Proposed Projects

1. Multi-Center Cohort Study To Assess the Risk and Consequences of 
Hepatitis C Virus Transmission From Mother to Infant (0920-0344)--
Extension

    The purpose of the study is to determine the incidence of vertical 
hepatitis C virus (HCV) transmission, to assess risk factors for 
vertical HCV transmission, to assess the clinical course of disease 
among infants with HCV infection, and to assess diagnostic methods for 
detecting HCV infection in infants. Respondents for the study will be 
anti-HCV positive mothers.
    There is no cost to the respondents. They will be remunerated for 
travel costs; provided well-child visits and free vaccinations for 
infants enrolled in the study; and, provided anti-HCV testing to all 
family members free of charge.

[[Page 49917]]



----------------------------------------------------------------------------------------------------------------
                                                                                          Average               
                                                               Number of    Number of     burden/       Total   
            Respondents                     Form name         respondents   responses/    response    burden (in
                                                                            respondent   (in hours)     hours)  
----------------------------------------------------------------------------------------------------------------
Individual Mothers.................  Form A.................          300            1         0.25           75
Mothers............................  Form B.................         1200            1         0.25          300
Mothers............................  Form C.................          300            1         0.10           30
Family members.....................  Form E.................          300            1         0.25           75
Mothers............................  Form G.................          300            8         0.10          240
      Total........................  .......................  ...........  ...........  ...........         *720
----------------------------------------------------------------------------------------------------------------
* The annualized response burden is estimated to be 720 hours/4.5 years=160 hours.                              
 AA(Target enrollment in the study is 300; the target population will be drawn from those who complete Form B.  
  Family members will complete Form E.)                                                                         

2. Evaluation of Antimicrobial Resistance Testing at National 
Nosocomial Infections Surveillance System (NNIS) Laboratories--New

    The Hospital Infections Program, National Center for Infectious 
Diseases (NCID), Centers for Disease Control and Prevention (CDC), is 
proposing to set up an evaluation program to validate the accuracy of 
the susceptibility data reported to the NNIS system. New and emerging 
mechanisms of antimicrobial resistant are becoming more common 
throughout the U.S. hospitals and have resulted in recommended changes 
in laboratory testing. However, the timing of changes in testing 
techniques commonly lag behind the recommended changes. Therefore, with 
antimicrobial resistance becoming more dispersed, validation of testing 
techniques is essential. The objectives of this project are to detect 
(1) unacceptable or inefficient methods of susceptibility testing, (2) 
inaccuracy due to technical difficulties, and (3) ineffective methods 
of reporting susceptibility data. The results from this project will 
help guide a campaign to improve antimicrobial testing in all U.S. 
hospitals. There is no cost to the respondents.

----------------------------------------------------------------------------------------------------------------
                                                                                         Average                
                                                            Number of     Number of      burden/    Total burden
                          Forms                            respondents   responses/   response (in   (in hours) 
                                                                         respondent      hours)                 
----------------------------------------------------------------------------------------------------------------
NNIS Hospital Laboratories..............................          230             1          0.30            77 
      Total.............................................  ............  ............  ............           77 
----------------------------------------------------------------------------------------------------------------

    Dated: September 14, 1998.
Charles Gollmar,
Deputy Director for Policy Planning and Evaluation, Centers for Disease 
Control and Prevention (CDC).
[FR Doc. 98-25033 Filed 9-17-98; 8:45 am]
BILLING CODE 4163-18-P